QNCX — Quince Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $46.77m
- $20.31m
- 18
- 23
- 35
- 14
Annual cashflow statement for Quince Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -76.8 | -89.9 | -51.7 | -31.4 | -56.8 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 15.5 | 30.9 | 17.4 | 11 | 25.2 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 10.2 | -4.26 | -9.73 | 2.01 | -0.484 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -50.8 | -62.9 | -44 | -18.3 | -31.9 |
| Capital Expenditures | -0.052 | -0.18 | -0.133 | -0.16 | -0.257 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -52.4 | 59.1 | 18.1 | -5.6 | 22.2 |
| Acquisition of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -52.4 | 59 | 18 | -5.76 | 21.9 |
| Financing Cash Flow Items | — | — | — | — | -5 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 119 | 6.81 | 0.707 | 0.143 | -4.78 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 15.6 | 2.88 | -25.1 | -23.8 | -14.5 |